JP2023537534A5 - - Google Patents
Info
- Publication number
- JP2023537534A5 JP2023537534A5 JP2023510439A JP2023510439A JP2023537534A5 JP 2023537534 A5 JP2023537534 A5 JP 2023537534A5 JP 2023510439 A JP2023510439 A JP 2023510439A JP 2023510439 A JP2023510439 A JP 2023510439A JP 2023537534 A5 JP2023537534 A5 JP 2023537534A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- fragment
- antibody
- polyspecific
- polyspecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2020/051959 WO2021032963A1 (en) | 2019-08-16 | 2020-08-14 | Therapeutic uses of anti-tcr delta variable 1 antibodies |
| GBPCT/GB2020/051959 | 2020-08-14 | ||
| GBGB2102224.9A GB202102224D0 (en) | 2021-02-17 | 2021-02-17 | Anti-TRC delta variable 1 antibodies |
| GB2102222.3 | 2021-02-17 | ||
| GB2102224.9 | 2021-02-17 | ||
| GBGB2102222.3A GB202102222D0 (en) | 2021-02-17 | 2021-02-17 | Multispecific anti-TCR delta variable 1 antibodies |
| PCT/IB2021/057509 WO2022034562A1 (en) | 2020-08-14 | 2021-08-14 | Multispecific anti-tcr delta variable 1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537534A JP2023537534A (ja) | 2023-09-01 |
| JP2023537534A5 true JP2023537534A5 (https=) | 2024-08-21 |
| JP7847579B2 JP7847579B2 (ja) | 2026-04-17 |
Family
ID=80247426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510439A Active JP7847579B2 (ja) | 2020-08-14 | 2021-08-14 | 多特異性抗ｔｃｒデルタ可変１抗体 |
Country Status (18)
| Country | Link |
|---|---|
| EP (7) | EP4265642B1 (https=) |
| JP (1) | JP7847579B2 (https=) |
| KR (1) | KR20230083267A (https=) |
| CN (1) | CN116209456A (https=) |
| AU (1) | AU2021323512A1 (https=) |
| BR (1) | BR112023002741A2 (https=) |
| CA (1) | CA3188682A1 (https=) |
| CO (1) | CO2023003009A2 (https=) |
| DK (2) | DK4010082T4 (https=) |
| ES (2) | ES2943063T3 (https=) |
| FI (2) | FI4010082T4 (https=) |
| IL (1) | IL300517A (https=) |
| LT (2) | LT4010082T (https=) |
| MX (1) | MX2023001728A (https=) |
| PL (2) | PL4269444T3 (https=) |
| PT (2) | PT4010082T (https=) |
| SI (2) | SI4010082T1 (https=) |
| WO (1) | WO2022034562A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4269444T3 (pl) | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| WO2023250485A1 (en) * | 2022-06-23 | 2023-12-28 | LAVA Therapeutics N.V. | Assay for t cell dependent multispecific compounds |
| WO2024193459A1 (en) * | 2023-03-17 | 2024-09-26 | Nanjing Legend Biotech Co., Ltd. | METHODS OF CULTURING Vδ1 T CELLS |
| WO2025147597A1 (en) * | 2024-01-05 | 2025-07-10 | Eugit Therapeutics, Inc. | Targeting payloads |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| WO2015063069A1 (en) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| AU2016274633B2 (en) | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| EP3344658B1 (en) | 2015-09-02 | 2022-05-11 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| WO2017072367A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Research Technology Limited | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS |
| US11299708B2 (en) | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| US20180028566A1 (en) | 2016-07-29 | 2018-02-01 | New York University | Gamma delta t cells as a target for treatment of solid tumors |
| US10546518B2 (en) | 2017-05-15 | 2020-01-28 | Google Llc | Near-eye display with extended effective eyebox via eye tracking |
| EP3645050A4 (en) | 2017-06-25 | 2021-08-11 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EP3743081A4 (en) | 2018-01-23 | 2021-12-01 | New York University | SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR |
| AU2019344300A1 (en) * | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| US12084500B2 (en) * | 2019-01-23 | 2024-09-10 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| CN113993893A (zh) * | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| CA3136251A1 (en) | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP7764364B2 (ja) | 2019-08-16 | 2025-11-05 | ガンマデルタ セラピューティクス リミティッド | エクスビボγδ Ｔ細胞集団 |
| PL4269444T3 (pl) | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| AU2022224391A1 (en) | 2021-02-17 | 2023-08-24 | Gammadelta Therapeutics Ltd | Anti-tcr delta variable 1 antibodies |
-
2021
- 2021-08-14 PL PL23187269.8T patent/PL4269444T3/pl unknown
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/en active Active
- 2021-08-14 ES ES21756070T patent/ES2943063T3/es active Active
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T4/fi active
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/en active Pending
- 2021-08-14 PL PL21756070.5T patent/PL4010082T5/pl unknown
- 2021-08-14 JP JP2023510439A patent/JP7847579B2/ja active Active
- 2021-08-14 CA CA3188682A patent/CA3188682A1/en active Pending
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 EP EP21756070.5A patent/EP4010082B9/en active Active
- 2021-08-14 SI SI202130032T patent/SI4010082T1/sl unknown
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 LT LTEP23187269.8T patent/LT4269444T/lt unknown
- 2021-08-14 FI FIEP23187269.8T patent/FI4269444T3/fi active
- 2021-08-14 DK DK21756070.5T patent/DK4010082T4/da active
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/en active Active
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/en active Active
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 DK DK23187269.8T patent/DK4269444T5/da active
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko active Pending
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/en active Active
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/en active Active
- 2021-08-14 SI SI202130192T patent/SI4269444T1/sl unknown
- 2021-08-14 PT PT231872698T patent/PT4269444T/pt unknown
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/en not_active Ceased
- 2021-08-14 ES ES23187269T patent/ES2993071T3/es active Active
-
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506682A5 (https=) | ||
| JP2023537534A5 (https=) | ||
| JP2023126852A5 (https=) | ||
| FI3535392T3 (fi) | Immunologisesti havaittavia solupintavariantteja käytettäväksi soluterapiassa | |
| JP2019533450A5 (https=) | ||
| JP2023515199A5 (https=) | ||
| JP7017506B2 (ja) | 系統特異的抗原の阻害のための組成物および方法 | |
| US20220403025A1 (en) | Therapeutic uses of anti-tcr delta variable 1 antibodies | |
| IL295897A (en) | Materials and methods for modulating an immune response | |
| JP2025513879A5 (https=) | ||
| JP2004528806A5 (https=) | ||
| US20060003452A1 (en) | Vector packaging cell line | |
| US20240382521A1 (en) | Methods of engineering immune cells having reduced fratricidal activity | |
| JP2025516377A (ja) | 多重特異性抗体を含む治療薬及び腫瘍治療におけるその使用 | |
| JP2025517657A5 (https=) | ||
| CA3236152A1 (en) | Compositions and methods for erm2 modification | |
| WO2023049926A2 (en) | Fusion polypeptides for genetic editing and methods of use thereof | |
| US20230414755A1 (en) | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors | |
| US20240344058A1 (en) | Compositions and methods for bcma modification | |
| Clark et al. | CD nomenclature 2015: human leukocyte | |
| JP2025530339A (ja) | 変異型ｒａｓを標的化するためのｔ細胞受容体及びその組成物 | |
| JP2025513894A5 (https=) | ||
| CN116744963A (zh) | 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物 | |
| Alaverdi | Monoclonal antibodies to mouse cell‐surface antigens | |
| EA048115B1 (ru) | Терапевтическое применение антител к tcr с вариабельной цепью дельта 1 |